NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development
NeOnc Technologies Holdings, Inc. announced that the Abu Dhabi Department of Health has granted Investigational New Drug status for NEO212, its oral conjugate therapy for aggressive brain tumors. This clearance follows the completion of the Phase 1 dose-escalation study, which identified 610 mg as the recommended Phase 2 dose and demonstrated early signs of clinical activity in pretreated patients. The authorization creates an international clinical pathway while the company continues discussions with the U.S.
Key figures
- Drug Name
- NEO212
- Phase Of Trial
- Phase 2
- Phase2 dose mg
- 610
- Patent protection until
- 2038
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.